RBC Capital Lowers Aerie Pharmaceuticals Price Target to $27.00 (AERI)
Analysts at RBC Capital cut their target price on shares of Aerie Pharmaceuticals (NASDAQ:AERI) from $28.00 to $27.00 in a research report issued to clients and investors on Tuesday, ARN reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s target price indicates a potential upside of 76.24% from the company’s current price.
A number of other analysts have also recently weighed in on AERI. Analysts at Stifel Nicolaus raised their price target on shares of Aerie Pharmaceuticals from $22.00 to $24.00 in a research note on Wednesday, March 19th. They now have a “buy” rating on the stock. Analysts at Needham & Company LLC raised their price target on shares of Aerie Pharmaceuticals from $22.00 to $26.00 in a research note on Wednesday, March 19th. They now have a “buy” rating on the stock.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 15.32 on Tuesday. Aerie Pharmaceuticals has a 52 week low of $10.25 and a 52 week high of $27.149. The stock has a 50-day moving average of $17.25 and a 200-day moving average of $16.99. The company’s market cap is $357.2 million.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.37. On average, analysts predict that Aerie Pharmaceuticals will post $-1.57 earnings per share for the current fiscal year.
Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.